small molecule

AUSTEDO

DEUTETRABENAZINE

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry
CompanyTEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D LLC

Drug detail

Brand nameAUSTEDO
Active ingredientDEUTETRABENAZINE
Strength9MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2017
Marketing statusRX

Listed patents

PatentExpiresType
11813232*PEDSeptember 2038
11179386*PEDSeptember 2038
11813232March 2038product
11179386March 2038product
11564917*PEDSeptember 2036
11648244*PEDSeptember 2036
11446291*PEDSeptember 2036
12016858*PEDSeptember 2036
11357772*PEDSeptember 2036
10959996*PEDSeptember 2036
11357772March 2036use U-3055
11648244March 2036use U-1995
12016858March 2036use U-3055
11446291March 2036use U-1995
10959996March 2036use U-3055
11564917March 2036use U-1995
9550780*PEDMarch 2034
9296739*PEDMarch 2034
9814708*PEDMarch 2034
11666566*PEDMarch 2034
9233959*PEDMarch 2034
9550780September 2033substance, product
9814708September 2033product
9296739September 2033product
11666566September 2033product
9233959September 2033product
8524733*PEDOctober 2031
8524733April 2031substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AUSTEDO patent cliff — loss of exclusivity September 2038 | CliffBio